Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer

Oncotarget

Volumn 8, Issue 35, 2017, Pages 58199-58209

  Tang, Yuanyuan ^a   Jiang, Shusuan ^a   Gu, Yinmin ^b   Li, Weidong ^b   Mo, Zengnan ^a,b   Huang, Yuanjie ^b   Li, Tianyu ^a,b   Hu, Yanling ^b  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Diagnostic biomarker; DNA methylation; Gene; Promoter; Prostate cancer

Indexed keywords

CG03576469; CG05385513; CG06363129; CG07220448; CG08843517; CG11417025; CG20883831; CG23824801; CYTOCHROME B LIGHT CHAIN; EGF CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1; MESSENGER RNA; PROTEIN CBX5; PROTEIN CCDC8; PROTEIN KCNH2; SCLEROSTIN DOMAIN CONTAINING PROTEIN 1; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SOLID MALIGNANT NEOPLASM; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

EID: 85029112566     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16437     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29. doi: 10.3322/caac.21208.
2. Lughezzani G, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, Fossati N, Lista G, Larcher A, Abrate A, Mistretta A, Bini V, Palou Redorta J, et al. Multicenter European external validation of a prostate health indexbased nomogram for predicting prostate cancer at extended biopsy. Eur Urol. 2014; 66:906-12. doi: 10.1016/j. eururo.2013.12.005.
3. Castillejos-Molina RA, Gabilondo-Navarro FB. Prostate cancer. Salud Publica Mex. 2016; 58:279-84.
4. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol. 2013; 63:986-94. doi: 10.1016/j. eururo.2013.01.011.
5. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011; 21:1017-27. doi: 10.1101/gr.119487.110.
6. White-Al Habeeb NM, Ho LT, Olkhov-Mitsel E, Kron K, Pethe V, Lehman M, Jovanovic L, Fleshner N, van der Kwast T, Nelson CC, Bapat B. Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget. 2014; 5:7858-69. doi: 10.18632/oncotarget.2313.
7. Piletic K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol. 2016; 90:2405-19. doi: 10.1007/s00204-016-1815-7.
8. Damaschke NA, Yang B, Blute ML Jr, Lin CP, Huang W, Jarrard DF. Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer. Neoplasia. 2014; 16:1018-27. doi: 10.1016/j.neo.2014.10.003.
9. Kim YW, Yoon HY, Seo SP, Lee SK, Kang HW, Kim WT, Bang HJ, Ryu DH, Yun SJ, Lee SC, Kim WJ, Kim YJ. Clinical implications and prognostic values of prostate cancer susceptibility candidate methylation in primary nonmuscle invasive bladder cancer. Dis Markers. 2015; 2015:402963. doi: 10.1155/2015/402963.
10. Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, Yu MW, Chen CJ, Santella RM. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology. 2012; 55:1799-808. doi: 10.1002/hep.25569.
11. Dai W, Cheung AK, Ko JM, Cheng Y, Zheng H, Ngan RK, Ng WT, Lee AW, Yau CC, Lee VH, Lung ML. Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. Cancer Med. 2015; 4:1079-90. doi: 10.1002/cam4.451.
12. Freeman JR, Chu S, Hsu T, Huang YT. Epigenome-wide association study of smoking and DNA methylation in nonsmall cell lung neoplasms. Oncotarget. 2016; 7:69579-91. doi: 10.18632/oncotarget.11831.
13. Klinkebiel D, Zhang W, Akers SN, Odunsi K, Karpf AR. DNA methylome analyses implicate fallopian tube epithelia as the origin for high-grade serous ovarian cancer. Mol Cancer Res. 2016; 14:787-94. doi: 10.1158/1541-7786. mcr-16-0097.
14. Collette NM, Yee CS, Hum NR, Murugesh DK, Christiansen BA, Xie L, Economides AN, Manilay JO, Robling AG, Loots GG. Sostdc1 deficiency accelerates fracture healing by promoting the expansion of periosteal mesenchymal stem cells. Bone. 2016; 88:20-30. doi: 10.1016/j.bone.2016.04.005.
15. Liu L, Wu S, Yang Y, Cai J, Zhu X, Wu J, Li M, Guan H. SOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation. Cell Biosci. 2016; 6:24. doi: 10.1186/s13578-016-0091-9.
16. Liang W, Guan H, He X, Ke W, Xu L, Liu L, Xiao H, Li Y. Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2. Oncotarget. 2015; 6:31780-91. doi: 10.18632/oncotarget.5566.
17. Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015; 75:2254-63. doi: 10.1158/0008-5472.can-14-2465.
18. Zhou H, Chen M, Zhu Y, Wang B, Liu XN, Zuo Z, Tang FY. Polymorphisms in NADPH oxidase CYBA gene modify the risk of ESRD in patients with chronic glomerulonephritis. Ren Fail. 2016; 38:262-7. doi: 10.3109/0886022x.2015.1117905.
19. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, Fox EJ, Culhane AC, McArdle L, Fraga MF, Hughes L, Currid CA, O'Mahony F, Byrne A, et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis. 2005; 26:1856-67. doi: 10.1093/carcin/bgi152.
20. Faller WJ, Rafferty M, Hegarty S, Gremel G, Ryan D, Fraga MF, Esteller M, Dervan PA, Gallagher WM. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Res. 2010; 20:392-400.
21. Lu JP, Monardo L, Bryskin I, Hou ZF, Trachtenberg J, Wilson BC, Pinthus JH. Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer Prostatic Dis. 2010; 13:39-46. doi: 10.1038/pcan.2009.24.
22. Li Q, Fu GB, Zheng JT, He J, Niu XB, Chen QD, Yin Y, Qian X, Xu Q, Wang M, Sun AF, Shu Y, Rui H, et al. NADPH oxidase subunit p22(phox)-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer. Biochim Biophys Acta. 2013; 1833:3375-85 doi: 10.1016/j.bbamcr.2013.09.018.
23. Yin X, Fang S, Wang M, Wang Q, Fang R, Chen J. EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway. Oncotarget. 2016; 7:47938-53. doi: 10.18632/oncotarget.10296.
24. Almeida M, Costa VL, Costa NR, Ramalho-Carvalho J, Baptista T, Ribeiro FR, Paulo P, Teixeira MR, Oliveira J, Lothe RA, Lind GE, Henrique R, Jeronimo C. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med. 2014; 18:2287-97. doi: 10.1111/jcmm.12394.
25. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, Kim WJ. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res. 2011; 17:4523-30. doi: 10.1158/1078-0432.ccr-10-2817.
26. Assenov Y, Muller F, Lutsik P, Walter J, Lengauer T, Bock C. Comprehensive analysis of DNA methylation data with RnBeads. Nat Methods. 2014; 11:1138-40. doi: 10.1038/nmeth.3115.
27. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28:882-3. doi: 10.1093/bioinformatics/bts034.
28. Peng HX, Yang L, He BS, Pan YQ, Ying HQ, Sun HL, Lin K, Hu XX, Xu T, Wang SK. Combination of preoperative NLR, PLR and CEA could increase the diagnostic efficacy for I-III stage CRC. J Clin Lab Anal. 2016 Sept 30. doi: 10.1002/jcla.22075. [Epub ahead of print]